



	Questions : Lok Sabha




























Screen Reader Access
Skip to Main Content
Skip to Navigation



Text Size

                                A

                                A
A















हिन्दी मे








Parliament of India Lok Sabha House of the
                        People






* Special Characters not allowed












India Time 


Your Time 


                        Monday,
                        11 April 2022









HomeMembersSitting MembersMembers Home PageMembers' PortalContact DetailsMembers SearchStatistical AnalysisAttendance of MembersHandbook Members Since 1952Digitized Who's WhoOthers BusinessProvisional CalendarList of BusinessPapers to be LaidList of Private Members' BusinessBulletin-IDigitized Lok Sabha Bulletin Part IBulletin-IIStatement of WorkSpecial Mentions (ZERO HOUR)Resume of WorkDigitized Resume of Work done by Lok Sabha QuestionsHomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions DebatesIntroductionSynopsisUncorrected DebateText of DebateDigitized DebatesConstituent Assembly DebatesWit And HumourDebate SearchHindi FontsDisclaimer Papers LaidPapers Laid on the Table of the House LegislationIntroduction(How Bill Becomes Act)Bills IntroducedBills PassedBills PendingBills AssentedBills LapsedBills WithdrawnBills NegativedBills Search Disclaimer CommitteesIntroductionChairpersonSummary of WorkCommittee Meetings ScheduleBills Referred to CommitteesReports PresentedDigitized ReportsPress ReleaseMembership SearchToday's Committee MeetingsCommittee Subject SelectedDepartment Related-RS Govt. AssurancesSANSAD TVIntranet





HomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions











Download as PDF




Print












PDF/WORD(Hindi)


PDF/WORD




                                    GOVERNMENT OF INDIA
                                





                                    MINISTRY OF
                                    SCIENCE AND TECHNOLOGY






                                    LOK SABHA
                                





UNSTARRED 


                                    QUESTION NO:
                                

2190






                                    ANSWERED ON: 
                                

23.09.2020






COVID-19 Pandemic




Uttam Kumar Nalamada Reddy














                        Will the Minister of





SCIENCE AND TECHNOLOGY


                        be pleased to state:-















                                                    a) The details of Government approved technology driven solutions and interventions toaddress the COVID-19 pandemic;b) The funds allocated for research of technology to address the pandemic;c) The details of plans to roll out these solutions to the public in order to protect peoplefrom the virus till a more permanent solution is found; andd) Whether any of these solutions have been implemented in Government offices and if so,the details thereof and if not, the reasons therefor?
                                                





ANSWER




                                                        MINISTER OF HEALTH & FAMILY WELFARE;MINISTER OF SCIENCE AND TECHNOLOGY;AND MINISTER OF EARTH SCIENCES(DR. HARSH VARDHAN)(a) & (b)During the current COVID-19 crisis, Government of India is working towards developmentof innovative technological interventions in terms of devices, diagnostics, vaccines,therapeutics & other related interventions through its various concerned Ministries andDepartments. In past few months, major focus has been put forth on fostering R&D supportto industries and academia towards development of diagnostic kits, therapeutics, vaccinesand other interventions like efficient sanitization methods, facial mask, Contactless DigitalSanitation etc. The budget allocated to different schemes for R&D is Rs.379.53 Crore. Thedetails of these activities are given in Annexure-A.(c) The technological interventions supported through various Ministries and their Departmentsin terms of diagnostics, therapeutics, PPEs, masks, sanitizers etc. are being used across thecountry in order to protect people from this COVID virus.(d) The various PPE, Masks and Diagnostic kits have been deployed across the countryincluding the Government offices.****Annexure -AA. Department of Biotechnology (DBT):The Department of Biotechnology (DBT) and its public sector undertaking Biotechnology IndustryResearch Assistance Council (BIRAC) have collaborated across the healthcare innovation ecosystemranging from biotech companies to entrepreneurs coming up with innovations to academic institutionsto address the COVID-19 global health care crisis. A call on COVID-19 Research Consortium wasannounced to support R&D proposals on devices, diagnostics, therapeutics, vaccine candidates andother interventions.1. Devices & Diagnostics: The Department has supported Infectious disease lab (I-Lab), which is amobile lab for COVID-19 testing under the National Biopharma Mission to the Andhra PradeshMed Tech Zone (AMTZ), Vishakapatnam in order to further enable testing access to rural India.The I-lab was launched by Hon’ble Minister S&T, MoHFW & MoES on 18thJun 2020. This canperform both RT-PCR and ELISA tests. The first lab is attached to THSTI hub and had performedabout 5000 tests in the Faridabad region. The Department is supporting17 proposals in the area ofDiagnostics with a total cost of 1000.93 lakhs.2. Therapeutics: Considering the present COVID crisis, the Department is supporting 13 proposals inthe area of Therapeutics with a total cost of Rs. 964.035 Lakhs. Of these, some of the targeted leadsare very much promising.3. Vaccine: Recognizing the critical requirement for a safe and efficacious vaccine for COVID-19, ineffective control of the pandemic, the Government of India, is supporting vaccine developmentactivities. Currently, nearly 30 vaccine candidates for COVID-19, based on multiple technologies /platforms are under development in India, by both academia and industry. Of these, the Departmentof Biotechnology is supporting 8 proposals by industry and 2 by academia for candidate vaccinedevelopment and associated research resources.A total cost of INR 75 crore has been allocated forsupporting vaccine development efforts. Availability of vaccine is subject to successful completionof Phase III clinical trials.4. Other interventions: In the area of Other Interventions, the Department is supporting 5 proposalswith a total cost of Rs. 86.88 Lakhs.5. Herbal Formulations: The Department is implementing3 Sub-Networks under “DBT-AYUSHNetwork Programme on R&D Activities related to SARS-CoV-2 Virus and COVID-19 Disease” ata total cost of ? 595.44 lakhs to be shared equally by DBT and National Medicinal Plants Board(NMPB), Ministry of AYUSH with an aim to screen selected traditional knowledge-basedmedicinal plants and classical formulations for anti-SARS-CoV-2 activities in cell culture modelsof virus infection. Studies are also planned to be carried out on preclinical and pharmacokineticsevaluation of selected AYUSH herbal extracts / formulations for mitigating SARS-CoV2 andassociated pathologies.The Department in collaboration with Biotechnology Industry Research Assistance Council(BIRAC) announced a Joint call on "Anti- SARS-CoV-2 /nCoV-2 Virus Studies using BotanicalIngredients and Traditional Formulations". Under this call, total 229 proposals were received forfurther processing.6. COVID-19 Bio-bank: As per the directives of Cabinet Secretary of National COVID-19 Biorepositoriesand recent ICMR notification, the Department is also supporting COVID-19 Biorepositoriesat following centers with a total cost of Rs. 1099.00 Lakhs:S.N Institute1. NCR-Biotech Science Cluster,a. Translational Health Science and Technology Institute (THSTI), Faridabadandb. Regional Centre for Biotechnology (RCB), Faridabad2. Institute for Stem Cell Science and Regenerative Medicine (inStem), Bangalore3. Institute of Life Sciences (ILS), Bhubaneswar4. National Centre for Cell Science (NCCS), Pune5. Institute of Liver and Biliary Sciences (ILBS), New Delhi (DBT-supported Biorepository)7. Under National Biopharma Mission, the Department is supporting technology driven solutionsand interventions to address COVID-19 pandemic broadly in the area of vaccines, devices anddiagnostics and therapeutics with a total investment of Rs. 222.crores. The details of technologiesunder support are as follows:Segment Technologies SupportedVaccines Vaccine - Development of recombinant vector vaccineVaccine - Phase III trial of rBCG vaccineVaccine - DNA vaccineVaccine - Development of Rabies vector based vaccineProduction of spike protein and receptor binding domainprotein of SARS CoV-2 for Diagnostic useVaccine evaluation animal model platformDiagnostics (n= 8 Diagnostic kits and2 manufacturing FacilitiesDiagnostic Technology (RT PCR test)Diagnostic Technology - (Colorimetric test)Diagnostic Technology (Lateral Flow assay based antigendetection test kit)Diagnostic Technology (ELISA kit)Diagnostic Technology (Swab testing)Diagnostic Technology (Rapid point of care detection kit)Diagnostic Technology (Scale up of virus detection kits)Diagnostic Technology (Lateral flow platform for viralantigen detection)Medi Tech Facility for manufacturing reagents and rawmaterials for diagnostic kitsMedi Tech Facility - Manufacturing facility for kits,ventilators and probesTherapeutics (n = 2) Antibody development from convalescent patient bloodand equine sourcesAntibody development from convalescent patient blood8. Biotechnology Industry Research AssistanceCouncil(BIRAC) support:a. Under the BIRAC’s Fast tracked Review and Funding support under COVID-19fund, 5 Start-ups have been approved.b. BIRAC - Research Consortium: BIRAC is supporting technology driven solutionsand interventions to address COVID-19 pandemic broadly within the area of vaccines,diagnostics and devices, therapeutics, Drugs and any other interventions. Under theBIRAC - Research Consortium Budget, a total investment of Rs. 10crores has beencommitted for COVID-19.B. Council of Scientific & Industrial Research (CSIR) is supporting various activities in thisarea. UnderNew Millennium Indian Technology Leadership Initiative (NMITLI) Scheme,six projects are being implemented at Rs. 965.600 lakh. Under a special Call, 36 projects arebeing implemented at Rs. 2541.54 lakh. The following activities are being supportedthrough CSIR:a. Diagnostics:FELUDA: CSIR-IGIB has developed indigenous novel Covid-19 diagnostic kit calledFELUDA (FNCAS9 Editor-Linked Uniform Detection Assay), a CRISPR-Cas9 basedtest licensed to TATA Sons. FELUDA has been approved by the Drug ControllerGeneral of India (DCGI). This is the only third CRISPR based technology in the worldto obtain regulatory approval for the detection of Coronavirus. The other methods usingCas12 and Cas13 proteins were developed by scientists at the University of California,Berkeley (UCB) and MIT in the USA. This method uses the FnCAS9 enzyme whichwas characterized and adapted for Covid19 detection at CSIR-IGIB. The detection relieson a simple visual readout using paper-based detection chemistry. It is rapid, sensitiveand specific. The entire method takes up to an hour, does not need high-endinstrumentation and can aid in scaling up the testing quickly in the country.b. Drug Development:? Favipiravir: CSIR-IICT has developed and patented the synthesis of Favipiravir. Ithas transferred the process to Cipla for manufacturing. Cipla has brought the drugto the market. Further, CSIR transferred the process to another 5 companies on nonexclusivebasis. This product is approved by DCGI as drug for mild and moderatepatients of Covid-19? Remdesivir: CSIR-IICT has developed process technology and handed over tocompanies that have got a license from Gilead. CSIR technology has resulted inproviding this drug at an affordable price to patients.c. Personal Protective Equipment (PPE):? Coverall: CSIR-NAL has developed high quality PPEs and transferred thetechnology to MAFL, Bengaluru. It has gone through stringent testing at SouthIndia Textile Research Association (SITRA), Coimbatore and has been certified toASTM F1670/F1670M-08(2014) for use. After certification, about one lakh pieceshave been supplied to Government. The current capacity of the production is7000/day which can be enhanced to 30,000/day depending upon requirement.? Face Mask: CSIR constituents laboratories have developed following face masks:i) High Efficiency Hydrophobic Three-Layered Facemask: The facemask iscomposed of two/three hydrophobic non-woven polypropylene (PP) layers in theouter and inner side and a ''High Efficiency Particulate Air'' filter in the middle.The performance of the developed mask certified from SITRA, Coimbatore.ii) Poly Ti:A Biopolymer Coated Medical Grade Mask: It is a two layered masksthat use biopolymer (Bacterial cellulose) coated mask, which are having muchhigher surface area and very fine nanofiber of cellulose to trap viruses andbacteria. It is developed using the patented technology of CSIR-NCL onBacterial cellulose. The performance of the developed mask certified fromSITRA, Coimbatore.iii) Reusable Face Mask with Antimicrobial Coating: It is a tri-layered maskwhich consists of the hydrophobic outer layer that repels the liquid aerosol andthe middle bactericidal layer to kill the microbes that comes in contact with themasks thereby providing dual protection benefits to the end-users. The innerhydrophilic layer absorbs the hot air, sweat and facilitates improvedbreathability. These masks and the coatings have been designed and formulatedto sustain up to 30-50 washes. The properties of the masks have been certifiedby SITRA, Coimbatore.C. AYUSH: Ayush Sanjivani mobile app developed by Ministry of AYUSH has been launchedto generate data on acceptance and usage of AYUSH advocacies and measures among thepopulation and its impact in prevention of COVID-19 targeting 05 million populations. Thismobile app is also having advisories related to need for self-care measures for immunityboosting and various Ayurvedic immunity promoting measures during COVID-19 crisis.D. Indian Council of Medical Research (ICMR): has validated 866 diagnostic commoditiesfor COVID-19. Out of this, 443 have been approved. Additionally, alternate indigenoustesting platforms like TrueNat and CBNAAT have also been validated and approved for use.These platforms have improved access to testing at district and primary health center level.Also, newer Rapid Antigen Tests have been validated and approved for use. This hasincreased access to testing at field level. Indigenization of technologies for COVID-19testing as well as handholding of indigenous manufacturers has tremendously helped inupscaling testing in India.E. Department of Science and Technology (DST):DST has announced a call on COVID -19 under Technology Development Board (TDB)and approved proposals and financial support for diagnostics development.
                                                    























HomeArchiveIndex to Select Questions (1984-1999)Ballot ListStatistical Statements Relating to QuestionsUploading of Questions - Status QueryProcedure for Sending Text of Questions & AnswersDemarcation of responsibilities in Govt. of IndiaBrochure on Statutory Corporations, Companies and Other Bodies in Which the Government of India have financial or controlling interestHighlights pertaining to questions of 17th Lok Sabha






Contact Us 
Disclaimer











        Developed and Hosted by National Informatics Centre (NIC)

Content on this website is published,
            managed & maintained by Software Unit, Computer (HW & SW) Management. Branch,
            Lok Sabha Secretariat





HomeMembersBusinessQuestionsDebatesPapers Laid


LegislationCommitteesSANSAD TVIntranetSecretariatPRIDE


RecruitmentSC/ST ReservationConferenceParliament Library


About ParliamentPhoto GalleryRelated LinksRTITendersFAQ


SpeakerDy. SpeakerLeader of the HousePanel of ChairpersonsContact UsFeedback


Council of MinistersPublications of MinistriesParliamentry ProceduresJournal of Parliamentary Information
Visitor's Counter:113197864







Copyright
Privacy Policy
Disclaimer
Terms &
                Conditions

                Accessibility Statement
Accessibility
                Options
Feedback
Site Map







